DIA439.32-0.83 -0.19%
SPX6,227.34-16.42 -0.26%
IXIC20,619.56-58.25 -0.28%

Aclarion Adds UHealth University Of Miami Miller School Of Medicine As CLARITY Trial Site To Validate Nociscan's AI-Driven MR Spectroscopy For Chronic Low Back Pain Surgery

Benzinga·06/10/2025 10:02:12
Listen to the news

Company announced the addition of UHealth — University of Miami Health System and the University of Miami Miler School of Medicine as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site. The landmark CLARITY study is designed to demonstrate Nociscan's clinical and economic value in spine surgery.

"I have a particular interest in ‘ultra-minimally' invasive approaches to the spine including endoscopic spine surgery," said Gregory Basil, MD, of UHealth who is also Director of Endoscopic Spine Surgery and Assistant Professor at the University of Miami Miller School of Medicine, University of Miami. "We believe in customizing treatments to each patient's pathology, goals, needs, and lifestyle, and in this regard, leveraging novel technologies, like Nociscan, to better understand our patient's low back pain for personalized treatments. The CLARITY trial is a unique opportunity for me and my colleagues at the Miller School of Medicine to advance the spine industry and showcase the research capabilities at the University of Miami."

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.